Fibrates, dyslipoproteinaemia and cardiovascular disease

Current Opinion in Lipidology

Volumn 10, Issue 6, 1999, Pages 561-574

  Watts, Gerald F ^a   Dimmitt, Simon B ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CERIVASTATIN; CLOFIBRATE; CREATINE KINASE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEINASE INHIBITOR; STATIN; TRIACYLGLYCEROL; WARFARIN;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD CLOTTING; CANCER; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIABETIC ANGIOPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DYSLIPOPROTEINEMIA; FIBRINOLYSIS; GALLSTONE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIVER DISEASE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RASH; RAT; REVIEW; RISK FACTOR; STOMACH PAIN; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLINICAL TRIALS; CLOFIBRIC ACID; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS;

NEXUS;

EID: 0033379344     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199912000-00011     Document Type: Review

References (122)

1. Buckner HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19:187-195.
2. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498-511. • A comprehensive, contemporary review of pharmacotherapy for lipid disorders.
3. Farmer JA. Aggressive lipid therapy in the statin era. Prog Cardiovasc Dis 1998; 41:71-94.
4. Genest JJ, McNamara JR, Salem DN, Shaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991; 67:1185-1189.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89:1329-1445.
6. Austin MA. Epidemiology of hypertriglyceridaemia and cardiovascular disease. Am J Cardiol 1999; 83:13F-16F.
7. Brewer HB. Hypertriglyceridemia: change in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 1999; 83:3F-12F.
8. Hokanson JE, Austin MA. Plasma triglyceride level as a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213-219.
9. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischaemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97:1029-1036. • A good epidemiological analysis supporting the independent roles of triglyceride and HDL-cholesterol levels in predicting cardiovascular disease, at least in men.
10. Miller M, Seidler A, Moalemi A, Pearson TA. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-term Study. J Am Coll Cardiol 1998; 31:1252-1257.
11. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882-888.
12. Sharrett AR, Sorlie PD, Chambless LE, Folsom AR, Hutchinson RG, Heiss G, Szklo M. Relative importance of various risk factors for asymptomatic carotid atherosclerosis versus coronary heart disease incidence: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999; 149:843-852.
13. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pagoda JM, LaBree L, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90:42-49.
14. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998; 18:20-26. • This study provides molecular insight into how hypertriglyceridaemia may impair fibrinolysis.
15. Boquist S, Ruotolo G, Tang R, Björkegren J, Bond MG, de Faire U, et al. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation 1999; 100:723-728.
16. Assman G, Schulte H. Relation of high-density lipoprotein cholesterol and triglyceride to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70:733-737.
17. Fruchart JC, Brewer HB, Leitersdorf E and members of the Fibrate Consensus Group. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998; 81:912-917. • The first consensus statement on the clinical use of fibrates; to be read with the balanced viewpoint provided by Sniderman [116•].
18. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98:2088-2093. •• A comprehensive summary of the novel aspects of the mechanism of fibrates on lipoprotein metabolism. Human studies are required to support the theories derived from in-vitro and rodent work.
19. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, et al. PPAR alpha and PPAR gamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15:5336-5348.
20. Hertz R, Bishara-Shieban J. Mode of action of peroxisome proliferators as hypolipidemic drugs, suppression of apolipoprotein C-III. J Biol Chem 1995; 270:13470-13475.
21. Haubenwallner S, Essenburg AD, Barnet BC. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res 1995; 36:2541-2551.
22. Schoonjans K, Watanabe M, Suzuki H. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 1995; 270:19269-19276.
23. Martin G, Schoonjans K, Lefebvre A. Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPARχ and PPARγ activators. J Biol Chem 1997; 272:28210-28217.
24. Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart J-C, et al. The nuclear receptors peroxisome proliferator-activated receptor χ and Rev-erbχ mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 1998; 273:25713-25720.
25. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995; 96:741-750.
26. Hennuyer N, Poulain P, Madsen L, Berge RK, Houdebine L-M, Braneller D, et al. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. Circulation 1999; 99:2445-2451. • Peroxisomal proliferation is potentially harmful; fenofibrate increased human A1 gene expression in rabbits independent of peroxisomal proliferation, indicating that a favourable effect on lipoprotein metabolism is achievable with subliminal activaion of PPARχ.
27. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998; 138:217-225. • An informative comparison of the metabolic and thrombo-fibrinolytic effects of two fibrates in treating mixed hyperlipidaemia; note the sample side of the study when drawing inferences. Although differences were noted, both bezafibrate and gemfibrozil have been shown to have favourable effects on the progression of coronary atherosclerosis in clinical trials.
28. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalises the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996; 16:763-772.
29. McPherson R, Agnani G, Lau P, Fruchart JD, Edgar AD, Marcel YL. Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-meditated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy. Arterioscler Thromb Vasc Biol 1996; 16:1340-1346.
30. Packard CJ. Overview of fenofibrate. Eur Heart J 1998; 19 (Suppl. A):A62-A65. • A summary of the molecular actions of fenofibrate, a fibric acid derivative that is being employed in several ongoing clinical trials.
31. Weintraub MS, Charach G, Grosskopf I. Effects of fibric acid derivatives and metformin on postprandial lipaemia. Atherosclerosis 1998; 141 (Suppl.):S71-75. • The mechanism for improvement in post-prandial lipaemia may differ with fibrates and metformin. One wonders about the additive effects that may translate into clinical benefit.
32. Lewis GF, Uffelman KD, Lamarche B, Cabana VG, Getz GS. Production of small high-density lipoprotein particles after stimulation of in vivo lipolysis in hyperlipoproteinaemic individuals: studies before and after triglyceride-lowering therapy. Metabolism 1998; 47:234-242.
33. Matsui H, Okumura K, Kawakami K, Hibino M, Toki Y, Ito T. Improved insulin sensitivity by bezafibrate in rats. Relationship to fatty acid composition of skeletal-muscle triglycerides. Diabetes 1997; 46:348-353.
34. Jeng C-Y, Sheu WH-H, Fuh MM-T, Shieh S-M, Chen Y-DI, Reaven GM. Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. J Clin Endocrinol Metab 1996; 81:2550-2553.
35. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999; 100:594-598. • The first demonstration that increasing apolipoprotein A1 pool size effects reverse cholesterol transport in humans.
36. La Ville AE, Sola R, Motta C, Plena N, Heras M, Ribalta J, Mosana L. Physiochemical changes in HDL3 after bezafibrate treatment: influence on free cholesterol efflux from human fibroblasts. Cardiovasc Drugs Ther 1997; 11:653-658.
37. Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. Atherosclerosis 1996; 121:1-12.
38. Liu R, Saku K, Jimi S, Ohta T, Zhang B, Takebayashi S, Arakawa K. Mechanism of action of gemfibrozil in HDL metabolism and atherosclerosis in WHHL rabbits. Cardiovasc Drugs Ther 1997; 11:659-668.
39. Yoshida H, Ishikawa T, Ayaori M, Shige H, Ilto T, Suzukawa M, Nakamura H. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study. Atherosclerosis 1998; 139:179-187.
40. Hoogerbrugge N, Kerkhofs LGM, Jansen H. Gemfibrozil decreases antibodies against oxidised low-density lipoprotein in men with combined hyperlipidaemia. J Intern Med 1998; 234:355-359.
41. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138:271-280.
42. Behar S. Lowering fibrinogen levels: clinical update. BIP Study Group. Bezafibrate Infarction Prevention. Blood Coag Fibrinolysis 1999; 10:S41-S43.
43. de Maat MPM, Knipscheer HC, Kastelein JJP, Kluft C. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia. Thromb Haemost 1997; 77:75-79.
44. Palazon CP, Alfon J, Gaffney P, Berrozpe M, Royo T, Bodimon L. Effects of reducing LDL and increasing HDL with gemfibrozil in experimental coronary lesion development and thrombotic risk. Atherosclerosis 1998; 136:333-345. • In spite of earlier reports that gemfibrozil increased plasma fibrinogen levels, this experimental study shows a reduction in fibrin deposition in arterial lesions.
45. Broijersen A, Eriksson M, Wiman B, Angelin B, Hjemdahl P. Gemfibrozil treatment of combined hyperlipoproteinaemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arterioscler Thromb Vasc Biol 1996; 16:511-516.
46. Kockx M, Princen HM, Kooistra T. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes: role of the peroxisome proliferator-activator receptor alpha. Thromb Haemost 1998; 80:942-948.
47. Jeng J-R, Jeng C-Y, Sheu WH-H, Lee MM-S, Huang S-H, Shieh S-M. Gemfibrozil treatment of hypertriglyceridemia: improvement of fibrinolysis without change of insulin resistance. Am Heart J 1997; 134:565-571.
48. Fruchart J-C, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999; 10:245-257. •• A most comprehensive review of the molecular effects of fibrates in experimental settings.
49. Inoue I, Shino K, Noji S, Awata T, Katagama S. Expression of peroxisome proliferator-activated receptor alpha (PPAR-alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998; 246:370-374. •• That PPARχ is expressed in endothelial cells provides an experimental rationale for the direct effects of fibrates on artery wall function.
50. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391:79-82.
51. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPAR gamma activators. Nature 1998; 393:790-793. •• This study shows the differential effects of PPARχ and PPARγ on smooth muscle cells. The full implications for the development of arterial lesions require further evaluation.
52. Colville-Nash PR, Qureschi SS, Willis D, Willoughby D. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. J Immunol 1998; 161:978-984. • Another pleiotropic effect of synthetic PPARχ agonists that would account for the findings in recent fibrate trials.
53. Murakami T, Mizuno S, Ohsato K, Moriuchi I, Arai Y, Nio Y, et al. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol 1999; 84:92-94.
54. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Huttunen JK, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245.
55. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347:849-853.
56. Ericsson C-G, Nilsson J, Grip L, Svane B, Hamsten A. Effect of bezafibrate over five years on coronary plaques causing 20% to 50% diameter narrowing. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Am J Cardiol 1997; 80:1125-1129.
57. Ruotolo G, Ericsson C-G, Tettamanti C, Karpe F, Grip L, Svane B, et al. Treatment effects on serum lipoproteins lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998; 32:1648-1656.
58. Frick MH, Syvänne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, et al.; the Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL-cholesterol. Circulation 1997; 96:2137-2143.
59. Humphries SE, Luong L-A, Talmud PJ, Frick MH, Kesaniemi YA, Paternack A, et al. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in the LOCAT gemfibrozil study. Atherosclerosis 1998; 139:49-56.
60. Andrews TC, Whitney EJ, Green G, Kalenian R, Personius BE. Effect of gemfibrozil±niacin±cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. Am J Cardiol 1997; 80:831-835.
61. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al., for the Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341:410-418. •• A seminal study showing that gemfibrozil decreases the incidence of coronary events in patients with low HDL, elevated triglyceride and normal LDL levels in a secondary prevention setting. Patients essentially exhibited the metabolic syndrome and significant numbers had non-insulin-dependent diabetes mellitus and hypertension and were smokers.
62. Papademetriou V, Narayan P, Rubins H, Collins D, Robins S, for the HIT Investigators. Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. Am Heart J 1998; 136:734-740.
63. Goldbourt U, Brunner D, Behar S, Reicher-Reiss H. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J 1998; 19:H42-H47. • This study reports the characteristics of the cohort of patients studied in BIP, the results of which are to be formally published shortly and summarised in our review with kind permission from the investigators.
64. Downs JR, Clearfield M, Weiss S, Whitney E, Shapiro DR, Beere PA, et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279:1615-1622. •• A study showing that a statin can decrease the incidence of coronary events in patients with low HDL and near-normal LDL-cholesterol levels in a primary prevention setting.Worth comparing the findings with those of VA-HIT and BIP.
65. Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, Goldbourt U, for the BIP Study. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) Registry. Circulation 1999; 100:475-482.
66. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol 1996; 16:351-356.
67. Ballantyne CM, Herd AJ, Ferli CLL, Dunn JK, Farmer JA, Jones PH, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999; 99:736-743.
68. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
69. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
70. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865.
71. Elkeles RS, Diamond JR, Poulter C, Dhanjel S, Nicolaides AN, Mahmood S, et al. The SENDCAP Study Group. Cardiovascular outcomes in Type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21:641-648. •• The first prospective trial showing that bezafibrate decreases the incidence of definite myocardial infarction in type 2 diabetic patients with dyslipidaemia. The principal endpoint of carotid IMT on ultrasonography was not, however, influenced by treatment. The method of selecting patients should be noted.
72. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J of Med 1999; 340:14-22.
73. Geroulakos G, Ramaswami G, Veller MG, Fisher GM, Renton S, Nicolaides A, et al. Arterial wall changes in type 2 diabetic subjects. Diab Med 1994; 11:692-695.
74. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hunninghake DB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90:1679-1689.
75. Hodis HN, Mack WJ, LaBree L, Selzer RH, Lin CR, Liu CH, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. A randomized, controlled clinical trial. Ann Intern Med 1996; 124:548-556.
76. Adams MR, Nakagomi A, Keech A, Robinson J, McCredie R, Bailey B, et al. Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation 1995; 92:2127-2134.
77. Migdalis IN, Gerolimou B, Kozanidou G, Voudouris G, Hatzigakis SM, Petropoulos A. Effect of gemfibrozil on early carotid atherosclerosis in diabetic patients with hyperlipidaemia. Int Angiol 1997; 16:258-261.
78. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15:820-825.
79. Pyörälä K, Pedersen TR, Kjekshus J, Faegeman O, Olsson AG, Thorgeirsson G. The Scandinavian Simvastatin Survival Study (4S). Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a sub-group analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614-620.
80. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, et al., for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Circulation 1998; 98:2513-2519.
81. American Diabetes Association. Management of dyslipidaemia in adults with diabetes. Diabetes Care 1999; 22 (Suppl. 1):S56-S59. • This study contains treatment recommendations for diabetic dyslipidaemia that rely principally on post-hoc analyses from statin trials. It may need revision with the results from newer fibrate trials.
82. Steiner G, for the DAIS Project Group. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in co-operation with the World Health Organisation. Diabetologia 1996; 39:1655-1661.
83. McLaughlin PR, Gladstone P, for the DAIS Project Group. Diabetes Atherosclerosis Intervention Study (DAIS): Quantitative coronary angiographic analysis of coronary artery atherosclerosis. Catheter Cardiovasc Diagn 1998; 44:249-256.
84. Hoogwerf BJ, Waness A, Cressman M, Canner J, Campeau L, Domanski M, et al., for the Post CABG Study Investigators. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. Diabetes 1999; 48:1289-1294.
85. Gholami K, Tavakoli N, Maleki M, Shafiee A. Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia. J Clin Pharmacol Ther 1998; 23:213-221.
86. Spencer CM, Barradell LB. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs 1996; 51:982-1018.
87. Goa KL, Barradell LB, Plosker GL. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs 1996; 52:725-753.
88. Schaefer EJ, Lamon-Fava S, Cole T, Sprecher DL, Cilla DD, Balagtas CC, et al. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolaemic patients with decreased HDL cholesterol levels. Atherosclerosis 1996; 127:113-122.
89. Ellen RLB, McPherson R. Long-term efficacy and safety of fenofibrate and a statin the treatment of combined hyperlipidemia. Am J Cardiol 1998; 81:60B-65B. • Efficacy and safety of fibrate/statin combination confirmed.
90. Zambon D, Ros E, Rodriguez-Villar C, Laguna JC, Vazquez M, Sanllehy C, et al. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidaemia: additive effects of combination treatment on lipid regulation. Metabolism 1999; 48:47-54.
91. Spencer GA, Wirebaugh S, Whitney EJ. Effect of a combination of gemfibrozil and niacin on lipid levels J Clin Pharmacol 1996; 36:696-700.
92. Bell DHS, Ovalle F. Troglitazone interferes with gemfibrozil's lipid-lowering action. Diabetes Care 1998; 21:2028-2029.
93. Perreault S, Hamilton VH, Lavoie F, Grover S. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidaemia. Cardiovasc Drugs Ther 1996; 10:787-794.
94. Sanllehy C, Casals E, Rodriguez-Villar C, Zambon D, Ojuel J, Ballesta AM, Ros E. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism 1998; 47:560-565.
95. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40:1069-1118.
96. Ganne-Carrie N, de Leusse A, Guettier C, Castera L, Levecq H, Bertrand HJ, et al. Autoimmune hepatitis induced by fibrates. Gastroenterol Clin Biol 1998; 22:525-529.
97. Lozada A, Dujovne CA. Drug interactions with fibric acids. Pharmacol Ther 1994; 63:163-176.
98. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234. • In this study, the importance of assigning all type 2 diabetic patients to high-risk secondary prevention strategies is underscored. Results are likely to be similar in non-Finnish populations.
99. Haffner SM. Diabetes, hyperlipidemia, and coronary artery disease. Am J Cardiol 1999; 83:17F-21F.
100. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1999; 22:S56-S59.
101. Tikkanen MJ, Laakso M, Ilmonen M, Helve E, Kaarsalo E, Kilkki E, Saltevo J, for the Study Group. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. Diabetes Care 1998; 21:477-481. • A clear demonstration of the optimal use of statins and fibrates in diabetic patients with lipid disorders.
102. Jeck T, Riesen WF, Keller U. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM. Diabetes Med 1997; 14:564-570.
103. O'Neal DN, O'Brien RC, Timmins KL, Grieve GD, Lau KP, Nicholson GC, et al. Gemfibrozil treatment increases low-density lipoprotein particle size in type 2 diabetes mellitus but does not alter in vitro oxidizability. Diabetes Med 1998; 15:870-877.
104. Zambrana JL, Lopez-Miraud J, Blanco A, Arizona JM, Jansen S, Paniagna JA, et al. Bezafibrate and lovastatin and decrease in the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlipidemia. J Heart Lung Transplant 1998; 17:1213-1219.
105. Attia N, Durlach V, Roche D, Paul J-L, Soni T, Zahouani A, et al. Post- prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment. Eur J Clin Invest 1997; 27:55-63.
106. Ginsberg HN, Le N-A, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins C-III and AI: evidence that apolipoprotein C-III inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986; 78:1287-1295.
107. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999; 83:25F-29F.
108. Muls E, Vam Gaal L, Autier P, Vansant G. Effects of initial BMI and on-treatment weight change on the lipid-lowering effect of fibrates. Int J Obesity 1997; 21:155-158.
109. Periard D, Telenti A, Sudre P, Cheseaux J-J, Halfon P, Reymond MJ, et al., for the Swiss HIV Cohort Study. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100:700-705. • This study highlights a new metabolic problem with potentially atherogenic implications for HIV patients on protease inhibitors. Drug interacts with lipid- regulating pharmacotherapy will also pose problems.
110. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-1883. • This paper presents a reasonable hypothesis for the aetiology of the metabolic syndrome that results in a proportion of HIV patients on protease inhibitors. Role of PPAR agonists in reversing complications require examination.
111. Carr A, Samaras K, Burton S, Low M, Freund J, Chisholm DJ, Cooper DJ. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-58. • This is the first description of the metabolic changes associated with the use of protease inhibitors. The significance of these abnormalities require further examination before prescribing lipid-regulating drugs for HIV-infected patients. Fibrates may interact with protease inhibitors and this could have several implications.
112. Henry K, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998; 352:1031-1032.
113. Samuelsson O, Attman P-O, Knight-Gibson C, Kron B, Larsson B, Mulec H, et al. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. Nephron 1997; 75:286-294.
114. Irish AB, Thompson CH. The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure. Nephrol Dial Transplant 1996; 11:2223-2228.
115. Attman P-O. Progression of renal failure and lipids is there evidence for a link in humans? Nephrol Dial Transplant 1998; 13:545-547.
116. Sniderman AD. Clinical trials, consensus conferences, and clinical practice. Lancet 1999; 354:327-330. • A typically thought-provoking essay from Professor Sniderman that should be considered seriously by all working in the domains referred to.
117. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendation of the Task Force of the European and other Societies on Coronary Prevention. Eur Heart J 1999; 19:1434-1503.
118. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British Recommendations on Prevention of Coronary Heart Disease in Clinical Practice. Heart 1998; 80 (Suppl. 2):S1-S29.
119. Durrington PN, Prais H, Bhatnagar D, France M, Crowley V, Khan J, Morgan J. Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet 1999; 353:278-281. •• This is a worrying comparison of cardiovascular risk assessment methods potentially used in clinical practice. HDL must be included in assessment, but there is still no clarification on the value of using the triglyceride level or related metabolic indices.Whether the application of neural networks will enhance the accuracy of the risk factor profile in predicting cardiovascular risk remains to be demonstrated.
120. Shulte H, Assman G. CHD risk equations, obtained from the Framingham Heart Study, applied to the PROCAM Study. Cardiovasc Risk Factors 1991; 1:126-133.
121. Garber AJ, Vinik AI, Crespin SR. Detection and management of lipid disorders in diabetic patients. Diabetes Care 1992; 15:1068-1074.
122. Rubenfire M, Coletti AT, Mosca L. Treatment strategies for management of serum lipids: lessons learned from lipid metabolism, recent clinical trials, and experience with the HMGCoA reductase inhibitors. Prog Cardiovasc Dis 1998; 41:95-116. • Independent and vigorous recommendations for the management of lipid disorders that are more far-sighted than those of more 'expert' bodies. To be read with Ref. 115 in mind.